R K R Rajoli1, A T Podany2, D M Moss3, S Swindells4, C Flexner5, A Owen1, M Siccardi1. 1. Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK. 2. College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska, USA. 3. Department of Molecular and Clinical Pharmacology, University of Liverpool, Liverpool, UK, School of Pharmacy, Keele University, Newcastle, UK. 4. College of Medicine, University of Nebraska Medical Center, Omaha, Nebraska. 5. Johns Hopkins University School of Medicine and Bloomberg School of Public Health, Baltimore, Maryland, USA.
Abstract
SETTING: Anti-tuberculosis formulations necessitate uninterrupted treatment to cure tuberculosis (TB), but are characterised by suboptimal adherence, which jeopardises therapeutic efficacy. Long-acting injectable (LAI) formulations or implants could address these associated issues. OBJECTIVE: niazid, rifapentine, bedaquiline and delamanid-in adults for treatment for latent tuberculous infection (LTBI). DESIGN: PBPK models were developed and qualified against available clinical data by integrating drug physicochemical properties and in vitro and population pharmacokinetic data into a mechanistic description of drug distribution. Combinations of optimal dose and release rates were simulated such that plasma concentrations were maintained over the epidemiological cut-off or minimum inhibitory concentration for the dosing interval. RESULTS: The PBPK model identified 1500 mg of delamanid and 250 mg of rifapentine as sufficient doses for monthly intramuscular administration, if a formulation or device can deliver the required release kinetics of 0.001-0.0025 h-1 and 0.0015-0.0025 h-1, respectively. Bedaquiline and isoniazid would require weekly to biweekly intramuscular dosing. CONCLUSION: We identified the theoretical doses and release rates of LAI anti-tuberculosis formulations. Such a strategy could ease the problem of suboptimal adherence provided the associated technological complexities for LTBI treatment are addressed.
SETTING: Anti-tuberculosis formulations necessitate uninterrupted treatment to cure tuberculosis (TB), but are characterised by suboptimal adherence, which jeopardises therapeutic efficacy. Long-acting injectable (LAI) formulations or implants could address these associated issues. OBJECTIVE:niazid, rifapentine, bedaquiline and delamanid-in adults for treatment for latent tuberculous infection (LTBI). DESIGN: PBPK models were developed and qualified against available clinical data by integrating drug physicochemical properties and in vitro and population pharmacokinetic data into a mechanistic description of drug distribution. Combinations of optimal dose and release rates were simulated such that plasma concentrations were maintained over the epidemiological cut-off or minimum inhibitory concentration for the dosing interval. RESULTS: The PBPK model identified 1500 mg of delamanid and 250 mg of rifapentine as sufficient doses for monthly intramuscular administration, if a formulation or device can deliver the required release kinetics of 0.001-0.0025 h-1 and 0.0015-0.0025 h-1, respectively. Bedaquiline and isoniazid would require weekly to biweekly intramuscular dosing. CONCLUSION: We identified the theoretical doses and release rates of LAI anti-tuberculosis formulations. Such a strategy could ease the problem of suboptimal adherence provided the associated technological complexities for LTBI treatment are addressed.
Authors: Suresh B Lakshminarayana; Tan Bee Huat; Paul C Ho; Ujjini H Manjunatha; Véronique Dartois; Thomas Dick; Srinivasa P S Rao Journal: J Antimicrob Chemother Date: 2014-11-11 Impact factor: 5.758
Authors: Helen Humphries; Lisa Almond; Alexander Berg; Iain Gardner; Oliver Hatley; Xian Pan; Ben Small; Mian Zhang; Masoud Jamei; Klaus Romero Journal: CPT Pharmacometrics Syst Pharmacol Date: 2021-10-08
Authors: Salmaan Keshavjee; Farhana Amanullah; Adithya Cattamanchi; Richard Chaisson; Karen M Dobos; Gregory J Fox; Howard E Gendelman; Richard Gordon; Anneke Hesseling; Hoi Le Van; Beate Kampmann; Bavesh Kana; Gopal Khuller; David M Lewinsohn; Deborah A Lewinsohn; Philiana Ling Lin; Lenette Lin Lu; Gary Maartens; Andrew Owen; Marina Protopopova; Jyothi Rengarajan; Eric Rubin; Padmini Salgame; Erwin Schurr; James A Seddon; Susan Swindells; David M Tobin; Zarir Udwadia; Gerhard Walzl; Sudha Srinivasan; Roxana Rustomjee; Payam Nahid Journal: Am J Respir Crit Care Med Date: 2019-03-01 Impact factor: 21.405